SOMATROGON

Written By:P. Thirumal ReddyB. Pharm Reviewed By:Dr. Tejashwin AdigaMBBS

Last updated on 31 Mar 2026 | 09:30 AM (IST)

SOMATROGON

Background and Date of approval SOMATROGON

Somatrogon is a long-acting recombinant human growth hormone (GH) analogue developed to address growth hormone deficiencies. It was approved by the U.S. FDA on January 21, 2022. Somatrogon, marketed under the name Ngenla, offers a more convenient weekly administration compared to daily injections of traditional growth hormone therapies.

Uses of SOMATROGON

Somatrogon is primarily used to treat pediatric patients with growth hormone deficiency (GHD), a condition where the body cannot produce adequate amounts of growth hormone. It helps promote normal growth in children with short stature due to insufficient GH levels.

How is SOMATROGON administered?

Somatrogon is administered as a subcutaneous injection, typically once a week. The dosage is individualised based on patient weight and treatment response. It is available in prefilled pens with different dose strengths, allowing flexible dosing for pediatric patients.

Side Effects of SOMATROGON

Common side effects of Somatrogon include injection site reactions, headaches, and gastrointestinal disturbances like nausea or vomiting. More severe adverse reactions may include hyperglycemia, joint pain, and, in rare cases, an elevated risk of malignancy or cardiovascular issues.

Warnings

Somatrogon use may increase the risk of developing serious side effects like intracranial hypertension, glucose intolerance, and impaired glucose control. Patients with active malignancy, acute critical illness, or those with closed epiphyses should avoid the drug. Close monitoring is required during treatment.

Precautions

Before starting Somatrogon, patients should be screened for hypothyroidism, as it can affect their response to the therapy. Due to potential effects on glucose metabolism, regular monitoring of blood sugar levels is advised. Patients with pre-existing conditions like scoliosis may experience worsening symptoms.

Word of Advice

Patients and caregivers should closely follow the prescribed dosage and administration schedule. Regular monitoring of growth and IGF-1 levels is important to assess treatment efficacy. If severe side effects occur, such as persistent headaches or changes in vision, consult your healthcare provider immediately.

Frequently Asked Questions

Q1.

What is the drug Somatrogon used for?

Somatrogon is used to treat pediatric patients with growth hormone deficiency (GHD), a condition where the body does not produce enough growth hormone. It helps children with short stature by promoting normal growth, bone development, and muscle strength, while also assisting in the regulation of metabolism.

Q2.

Can adults use Somatrogon?

Somatrogon is currently approved for pediatric use, but studies on adults may be ongoing.

Q3.

How does Somatrogon differ from traditional GH therapies?

Somatrogon is administered once a week, whereas traditional GH therapies require daily injections.

Q4.

Who should avoid using Somatrogon?

Patients with active cancer, critical illness, or closed growth plates should avoid Somatrogon.

Q5.

How long does it take for Somatrogon to show results?

The response to Somatrogon may vary by individual, but improvement in growth is typically seen after several weeks of consistent use. Your doctor will monitor progress regularly.

Q6.

Is Somatrogon safe for long-term use?

Somatrogon is designed for long-term use in patients with growth hormone deficiency. Regular monitoring by your healthcare provider is essential to ensure safety and effectiveness over time.